Synergistic interactions with PI3K inhibition that induce apoptosis
Yaara Zwang1,2, Oliver Jonas3, Casandra Chen1,2
1Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, United States.
Abstract:
Activating mutations involving the PI3K pathway occur frequently in human cancers. However, PI3K inhibitors primarily induce cell cycle arrest, leaving a significant reservoir of tumor cells that may acquire or exhibit resistance. We searched for genes that are required for the survival of PI3K mutant cancer cells in the presence of PI3K inhibition by conducting a genome scale shRNA-based apoptosis screen in a PIK3CA mutant human breast cancer cell. We identified 5 genes (PIM2, ZAK, TACC1, ZFR, ZNF565) whose suppression induced cell death upon PI3K inhibition. We showed that small molecule inhibitors of the PIM2 and ZAK kinases synergize with PI3K inhibition. In addition, using a microscale implementable device to deliver either siRNAs or small molecule inhibitors in vivo, we showed that suppressing these 5 genes with PI3K inhibition induced tumor regression. These observations identify targets whose inhibition synergizes with PI3K inhibitors and nominate potential combination therapies involving PI3K inhibition.
Insights
This study identifies five genes crucial for cancer cell survival under PI3K inhibition. Suppressing these genes, along with PI3K inhibitors, leads to tumor regression, suggesting new combination therapies.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Activating mutations in the PI3K pathway are common in human cancers.
- PI3K inhibitors often induce cell cycle arrest, leading to resistant tumor cell populations.
Purpose of the Study:
- To identify genes essential for the survival of PI3K-mutant cancer cells during PI3K inhibition.
- To explore novel therapeutic targets and combination strategies for PI3K-mutant cancers.
Main Methods:
- Genome-scale shRNA-based apoptosis screen in a PIK3CA-mutant human breast cancer cell line.
- Validation using small molecule inhibitors of identified kinases (PIM2, ZAK).
- In vivo studies utilizing a microscale device for siRNA and small molecule inhibitor delivery.
Main Results:
- Five genes (PIM2, ZAK, TACC1, ZFR, ZNF565) were identified as essential for survival upon PI3K inhibition.
- Small molecule inhibitors of PIM2 and ZAK kinases synergized with PI3K inhibition.
- In vivo suppression of these genes combined with PI3K inhibition resulted in tumor regression.
Conclusions:
- Targeting PIM2, ZAK, TACC1, ZFR, and ZNF565 represents a promising strategy to overcome PI3K inhibitor resistance.
- Combination therapies involving PI3K inhibitors and inhibitors of these newly identified genes warrant further investigation for cancer treatment.
More Related Videos
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
08:49Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
Related Concept Videos
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
The Intrinsic Apoptotic Pathway
PI3K/mTOR/AKT Signaling Pathway
The JAK-STAT Signaling Pathway
Inhibition of Cdk Activity
The Extrinsic Apoptotic Pathway
